Evidence map›Paper›PMID 39849231›Full record

ArticleJournal of cancer research and clinical oncology2025

Stromal PDGFR-beta expression is a prognostic factor in high-grade serous ovarian cancer patients but is it also predictive for response to antiangiogenic treatment?

Annabelle Volk, Charlotte von Bülow, Aysche Stern, Ronald Simon, Eike Burandt, Guido Sauter, Barbara Schmalfeldt, Leticia Oliveira-Ferrer

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of cancer research and clinical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Annabelle Volk *Department of Gynecology, University Medical Center Hamburg-Eppendorf, Martinistrasse 52, 20246, Hamburg, Germany. an.volk@uke.de.
Charlotte von Bülow *Department of Gynecology, University Medical Center Hamburg-Eppendorf, Martinistrasse 52, 20246, Hamburg, Germany.
Aysche SternDepartment of Gynecology, University Medical Center Hamburg-Eppendorf, Martinistrasse 52, 20246, Hamburg, Germany.
Ronald SimonDepartment of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Eike BurandtDepartment of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Guido SauterDepartment of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Barbara SchmalfeldtDepartment of Gynecology, University Medical Center Hamburg-Eppendorf, Martinistrasse 52, 20246, Hamburg, Germany.
Leticia Oliveira-FerrerDepartment of Gynecology, University Medical Center Hamburg-Eppendorf, Martinistrasse 52, 20246, Hamburg, Germany.

Funding

Wilhelm Sander-Stiftung 2017.088.1
6 · The paper itself

Abstract

objectiveIn advanced ovarian cancer, the majority of patients receive anti-angiogenic treatment with bevacizumab. However, its use is often associated with severe side effects, and not all patients benefit from the therapy. Currently, there are no reliable biomarkers to predict response to treatment. Given their role as key regulators of angiogenesis, platelet-derived growth factor receptor-beta (PDGFR-beta) and vascular endothelial growth factor receptor-2 (VEGFR-2) are promising candidates for predictive biomarkers. This study evaluates their potential.

methodsPDGFR-beta and VEGFR-2 expression was evaluated using immunohistochemistry in a tissue microarray assay including 391 ovarian tissue samples. Correlation analyses with clinical and histopathological parameters were performed in a homogeneous cohort of 199 high grade serous ovarian cancer samples (HGSOC).

resultsIn HGSOC, strong stromal PDGFR-beta expression was associated with significantly shorter overall survival compared to weak/moderate expression. The impact of stromal PDGFR-beta expression on patient survival was however not restricted to the subgroup of patients receiving therapy with bevacizumab, and therefore cannot be considered as a predictive factor. For VEGFR-2, no or weak protein expression was found in the majority of the tumor samples. Survival analyses showed a more favorable prognosis with no or weak VEGFR-2 expression.

conclusionsHigh stromal expression levels of PDGFR-beta correlate with shorter overall survival in HGSOC. Thus, stromal PDGFR-beta might serve as a prognostic biomarker. No predictive effect in response to bevacizumab therapy could be attributed.

Indexed as

Angiogenesis InhibitorsBiomarkers, TumorCystadenocarcinoma, SerousOvarian NeoplasmsReceptor, Platelet-Derived Growth Factor betaAdultAgedAged, 80 and overBevacizumabFemaleHumansImmunohistochemistryMiddle AgedNeoplasm GradingPrognosisVascular Endothelial Growth Factor Receptor-2Angiogenesis InhibitorsBevacizumabBiomarkers, TumorKDR protein, humanPDGFRB protein, humanReceptor, Platelet-Derived Growth Factor betaVascular Endothelial Growth Factor Receptor-2BevacizumabOvarian cancerPDGFR-betaPrognostic biomarkerVEGFR-2

Identifiers

PMID39849231
PMCPMC11759463

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.